Injunction raises questions over regulation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The commercialization of university-based research: Balancing risks and benefits
BMC Medical Ethics Open Access 14 October 2015
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related external links
International Cellular Medicine Society
Regenexx/Regenerative Sciences
Rights and permissions
About this article
Cite this article
Cyranoski, D. FDA challenges stem-cell clinic. Nature 466, 909 (2010). https://doi.org/10.1038/466909a
Published:
Issue date:
DOI: https://doi.org/10.1038/466909a
This article is cited by
-
The commercialization of university-based research: Balancing risks and benefits
BMC Medical Ethics (2015)
-
The global industry for unproven stem cell interventions and stem cell tourism
Tissue Engineering and Regenerative Medicine (2014)
-
Opportunities and barriers to establishing a cell therapy programme in South Africa
Stem Cell Research & Therapy (2013)
-
Recent Developments in Health Care Law: Culture and Controversy
HEC Forum (2013)
-
Stem-cell therapy takes off in Texas
Nature (2012)
